Sona Nanotech’s THT Cancer Therapy Preclinical Efficacy Studies Published In Peer-Reviewed Scientific Journal
Halifax, Nova Scotia--(Newsfile Corp. - January 13, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is...
Day: January 13, 2025
Hemostemix Settlement via Depository Trust Company Plus OTCQB Update
Calgary, Alberta--(Newsfile Corp. - January 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")...
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited)Updates...
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing...
Vaso Corporation Announces Executive Leadership Appointments & Names New Vice Chairman to the Board of Directors
PLAINVIEW, N.Y, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leader in human capital, information technology...
NeurAxis Inc. Issues Letter to Shareholders
CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology...
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12
The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected...
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward...
VIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025
CAMPBELL, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of...
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including...
Clover Health Reports 27% Growth in Medicare Advantage Membership, Surpassing 100,000 Lives After Strong Annual Election Period
Robust plan benefits powered member growth, mainly driven by switchers from other plansCompany will focus on balancing profitability with strategic...
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024
Fourth Quarter 2024 worldwide revenue of ~$48.8 to $49.0 million representing growth of ~26%Achieved adjusted EBITDA profitability in the fourth...
Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation
Entering 2025 having demonstrated rapid translation of genetic insights to positive clinical data; advancing clinically validated and multi-modal pipeline with...
Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch
More patients treated with ZTlido® saw either a decrease or discontinuation of opioid use compared with those treated with the...
Clinical Trial of NeuroSigma’s Monarch eTNS System for ADHD at King’s College London Completes Enrollment
ATTENS (ADHD trial of external trigeminal nerve stimulation) Project, led by Professor Katya Rubia at the Institute of Psychiatry, Psychology...
ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9
The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An Express License provides fast,...
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea preparing icovamenib for late-stage clinical development2025 corporate...
New Standard for Medtech Alternate Equipment Management (AEM)
AAMI Document Clarifies Repair RequirementsArlington, VA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Alternate equipment management (AEM) plans for medical devices...
Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762
Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell CarcinomaMarlborough, Massachusetts--(Newsfile Corp. - January 13, 2025) - Phio...
Optimi Health Reports First Patients Dosed in Landmark Natural Psilocybin Study in New Zealand
The Company's natural psilocybin extract powers a culturally transformative study to address methamphetamine addiction through indigenous frameworks.Vancouver, British Columbia--(Newsfile Corp....